Strs Ohio Purchases 83,706 Shares of Danaher Corporation $DHR

Strs Ohio increased its position in Danaher Corporation (NYSE:DHR) by 33.5% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 333,397 shares of the conglomerate’s stock after acquiring an additional 83,706 shares during the period. Strs Ohio’s holdings in Danaher were worth $66,099,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. White Pine Capital LLC lifted its stake in Danaher by 1.4% during the 2nd quarter. White Pine Capital LLC now owns 3,494 shares of the conglomerate’s stock valued at $690,000 after acquiring an additional 49 shares during the period. SOL Capital Management CO lifted its position in Danaher by 2.8% during the third quarter. SOL Capital Management CO now owns 1,829 shares of the conglomerate’s stock valued at $363,000 after purchasing an additional 50 shares during the period. Boyd Watterson Asset Management LLC OH boosted its holdings in Danaher by 2.1% in the second quarter. Boyd Watterson Asset Management LLC OH now owns 2,524 shares of the conglomerate’s stock worth $499,000 after purchasing an additional 51 shares during the last quarter. Worth Financial Advisory Group LLC raised its stake in Danaher by 4.6% during the 2nd quarter. Worth Financial Advisory Group LLC now owns 1,195 shares of the conglomerate’s stock valued at $236,000 after buying an additional 53 shares during the last quarter. Finally, Howard Capital Management Group LLC lifted its holdings in shares of Danaher by 4.8% during the 3rd quarter. Howard Capital Management Group LLC now owns 1,159 shares of the conglomerate’s stock valued at $230,000 after buying an additional 53 shares during the period. 79.05% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. Jefferies Financial Group increased their target price on Danaher from $245.00 to $255.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. Rothschild Redb downgraded shares of Danaher from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 8th. Barclays boosted their price target on Danaher from $225.00 to $250.00 and gave the company an “overweight” rating in a report on Wednesday, October 22nd. Deutsche Bank Aktiengesellschaft boosted their price objective on Danaher from $235.00 to $250.00 and gave the company a “buy” rating in a research note on Wednesday, October 22nd. Finally, Evercore ISI reissued an “outperform” rating and issued a $250.00 price objective on shares of Danaher in a research note on Monday, January 5th. Twenty research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $252.09.

Insider Transactions at Danaher

In related news, SVP Georgeann Couchara sold 5,174 shares of the stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $210.42, for a total value of $1,088,713.08. Following the completion of the transaction, the senior vice president owned 2,625 shares of the company’s stock, valued at approximately $552,352.50. This trade represents a 66.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Teri List sold 3,298 shares of Danaher stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $226.50, for a total value of $746,997.00. Following the completion of the transaction, the director owned 20,762 shares of the company’s stock, valued at approximately $4,702,593. This trade represents a 13.71% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 30,248 shares of company stock worth $6,609,663 in the last three months. Insiders own 11.10% of the company’s stock.

Danaher Stock Down 0.9%

DHR opened at $239.99 on Friday. The company has a market capitalization of $169.52 billion, a PE ratio of 49.48, a price-to-earnings-growth ratio of 3.68 and a beta of 0.89. The firm has a 50-day simple moving average of $229.99 and a two-hundred day simple moving average of $212.84. The company has a quick ratio of 1.10, a current ratio of 1.52 and a debt-to-equity ratio of 0.33. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $258.23.

Danaher (NYSE:DHR) last released its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share for the quarter, beating the consensus estimate of $1.72 by $0.17. The business had revenue of $6.05 billion during the quarter, compared to analysts’ expectations of $6 billion. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The firm’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same quarter last year, the business posted $1.71 EPS. Analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Friday, December 26th will be given a dividend of $0.32 per share. The ex-dividend date is Friday, December 26th. This represents a $1.28 annualized dividend and a yield of 0.5%. Danaher’s dividend payout ratio (DPR) is 26.39%.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.